Fierce Biotech April 2, 2024
Eko Health has secured a groundbreaking clearance from the FDA for an artificial intelligence program that can capture a key indicator of heart performance through its digitally enhanced stethoscopes.
Developed in collaboration with the Mayo Clinic, the software can detect cases of low ejection fraction—a primary sign of heart failure, where the beating organ is unable to efficiently pump out blood to the rest of the body with each heartbeat.
Heart failure is typically split between patients with reduced ejection fraction, a condition known as HFrEF, and those with preserved levels, with a complete diagnosis typically requiring a specialized ultrasound exam. Eko estimates more than 3 million people in the U.S. may have HFrEF, with many going untreated.
“The ability...
Today's Sponsors
Today's Sponsor